A Study of the Safety and Tolerability of AB-2004 in a Pediatric Autism Spectrum Disorder Population
We are working with Axial and three other sites to assess the safety, tolerability and efficacy of a pharmaceutical therapy called AB-2004.
Phase 1b/2a of the study explored whether AB-2004’s ability to reduce the availability of certain gut bacteria, such as p-cresol, can improve gastrointestinal symptoms and some related behavioural challenges in autistic individuals.
Phase 2b of the study is now underway, investigating whether treatment with AB-2004 can improve irritability in autistic children. Eligible participants will be randomly assigned to receive AB-2004 or a placebo.
You can read more on the study's website.